Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Apply
Ocrelizumab & rHuPH20
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step